Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-medicare

Griffiths RI, Gleeson ML, Mikhael J, Danese MD

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1155/2012/978391

Original Paper URL
http://www.hindawi.com/journals/jce/2012/978391/abs/

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Lymphoma, Follicular; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aged; Aged, 80 and over

AccessionNumber
22012035734

Date bibliographic record published
14/02/2013